Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors

Next Previous
Trial Profile

A Phase 1/2 Study of RTX-224 for the Treatment of Patients With Advanced Solid Tumors

Status: Discontinued
Phase of Trial: Phase I/II

Latest Information Update: 14 Dec 2022

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs RTX 224 (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Carcinoma; Head and neck cancer; Malignant melanoma; Non-small cell lung cancer; Solid tumours; Squamous cell cancer; Triple negative breast cancer; Urogenital cancer
  • Focus Adverse reactions; First in man
  • Sponsors Rubius Therapeutics [CEASED]

Most Recent Events

  • 13 Sep 2022 Status changed from recruiting to discontinued, according to a Rubius Therapeutics media release.
  • 13 Sep 2022 According to a Rubius Therapeutics media release, the company plans to restructure the company and align resources to advance its next generation red blood cell-based cell conjugation platform. Hence the company decided to discontinue this study.
  • 13 Sep 2022 According to a Rubius Therapeutics media release, 36 patients have been dosed in the monotherapy arm of the Phase 1/2 clinical trial of RTX-240 in advanced solid tumors, as of September 12, 2022 and Fourteen patients were dosed in the "all comers" dose-escalation portion of the Phase 1 clinical trial evaluating RTX-240 in combination with pembrolizumab in advanced solid tumors.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top